168
Participants
Start Date
April 7, 2022
Primary Completion Date
July 1, 2026
Study Completion Date
July 1, 2027
Modi-1 Moditope
Modi-1 Moditope administered intradermally (i.d.) using the MicronJet600™ microneedle device (NanoPass).
Pembrolizumab
Pembrolizumab (exploratory cohorts) will be administered by intravenous infusion on Day 8, prior to tumour resection surgery at 6 weeks.
MicronJet600™ microneedle device (NanoPass)
Intradermal injection device
ACTIVE_NOT_RECRUITING
Brighton and Sussex University Hospital, Brighton
RECRUITING
Velindre Cancer Centre, Cardiff
RECRUITING
Edinburgh Cancer Centre (NHS Lothian), Edinburgh
RECRUITING
Royal Surrey NHS Foundation, Guildford
ACTIVE_NOT_RECRUITING
Imperial College Healthcare NHS Trust, London
RECRUITING
Mount Vernon, London
RECRUITING
University College London Hospital NHS Foundation Trust, London
RECRUITING
Christie NHS Foundation Trust, Manchester
RECRUITING
Nottingham University Hospitals Cancer Centre, Nottingham
RECRUITING
Lancashire Teaching Hospitals NHS Foundation Trust, Preston
RECRUITING
Sheffield Teaching Hospital NHS Foundation Trust, Sheffield
NOT_YET_RECRUITING
The Royal Marsden NHS Foundation Trust, Sutton
RECRUITING
Belfast City Hospital, Belfast
RECRUITING
Addenbrooke's Hospital, Cambridge University Hospitals, Cambridge
RECRUITING
Torbay and South Devon NHS Foundation Trust, Torquay
RECRUITING
The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool
Scancell Ltd
INDUSTRY